BRD9
| Official symbol: | BRD9 |
| Full name: | bromodomain containing 9 |
| Location: | 5p15.33 |
| Also known as: | FLJ13441 |
| Entrez ID: | 65980 |
| Ensembl ID: | ENSG00000028310 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 2.81 (Driver) | | Gscore (Del): | 0.13 |
|
|
| Recurrently amplified in 9 cancer type(s) | | Recurrently deleted in 1 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 5 |
|
|
| Fusions detected in 3 cancer type(s) |
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
RNAi: STRONGLY SELECTIVE
|
|
|
| |
|
|
|
| Functional class: | Epigenetic |
| JensenLab PubMed score: | 24.75 (Percentile rank: 50.98%) |
| PubTator score: | 5.87 (Percentile rank: 31.14%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | |
